Clinical Trial Update: Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder [Phase 2]

View source ↗

Summary

This update indicates that ITI-1284 is being studied as a monotherapy for generalized anxiety disorder in a Phase 2 trial and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Anxiety Disorder

Drugs mentioned

• ITI-1284

Snippet

Sponsor: Intra-Cellular Therapies, Inc. | Conditions: Generalized Anxiety Disorder | Phase 2 | Status: RECRUITING